Physician profile
Young Park
NPI 1083094189
$2,640.26
in general payments reported to CMS, 2019-2025
23 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $208 · 2021: $779 · 2022: $449 · 2023: $52.58 · 2024: $24.00 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.04 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $427.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Welch Allyn | $355.82 | 2019 | |
| Nevro Corp. | $214.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $195.36 | 2019-2021 | |
| Daiichi Sankyo INC. | $131.24 | 2020-2021 | |
| Amgen INC. | $130.32 | 2021-2025 | Otezla, Repatha |
| Lilly USA, LLC | $115.79 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $105.35 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Esperion Therapeutics, INC. | $78.32 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $69.69 | 2021 | |
| Jazz Pharmaceuticals INC. | $60.92 | 2019-2021 | |
| Pfizer INC. | $59.01 | 2021 | |
| Abbvie INC. | $49.64 | 2019-2021 | |
| Abbott Laboratories | $47.94 | 2022-2025 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.28 | 2019-2020 | |
| Exact Sciences Corporation | $34.74 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $16.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.36 | 2023 | Xarelto |
| Redhill Biopharma INC. | $15.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.83 | 2019 | |
| Althera Pharmaceuticals LLC | $9.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.